10 recruiting, 5 not yet recruiting, 3 withdrawn, 2 active not recruiting. 9 Phase 1, 5 Not applicable, 2 Early Phase 1, 1 Phase 2, 1 Phase 4.
Follow CAR-T Cell Therapy: new trials by email Literature Review of CAR-T Cell Therapy trials Research Report on CAR-T Cell Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INfections in Patients Treated With CAR-T Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 290 | 2026-11-01 | 2026-07-20 | |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2026-11-01 | 2026-10-26 |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC TC-D101 CAR-T - Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy | Early Phase 1 | Recruiting | TCRCure Biopharma Ltd. | 24 | 2026-06-10 | 2026-10-26 |
| RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) - CAR-T Cell Therapy, RSV Immunization | Phase 4 | Not yet recruiting | The Cooper Health System | 30 | 2026-01-01 | 2025-12-22 |
| A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 CNCT-19 - ALL (Acute B-Lymphoblastic Leukemia), CAR-T Cell Therapy | Active not recruiting | Ruijin Hospital | 275 | 2025-11-07 | 2025-12-10 | |
| A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia A-CAR028 - Acute Myeloid Leukemia (AML), CAR-T Cell Therapy | Phase 1 | Recruiting | First Affiliated Hospital of Zhejiang University | 20 | 2025-09-30 | 2025-09-30 |
| Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients - CLL, CAR-T Cell Therapy | Not applicable | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-13 |
| Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS anti-CD19 CAR-T cells - Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy | Phase 1 | Withdrawn | The Children's Hospital of Zhejiang University School of Medicine | 2025-05-14 | 2026-06-16 | |
| Nutrition OUtReach In Systems of Healthcare Food Bags - ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant | Not applicable | Recruiting | University of Kansas Medical Center | 210 | 2025-05-01 | 2026-04-20 |
| Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma Axicabtagene Ciloleucel - CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL) | Not applicable | Not yet recruiting | Ruijin Hospital | 60 | 2025-04-30 | 2025-04-22 |
| Coping Skills Training for Symptom Management and Daily Steps (Step Up) Step Up, Usual Care Plus (UC+) - Hematopoietic Stem Cell Transplant, CAR-T Cell Therapy | Not applicable | Recruiting | Duke University | 177 | 2025-04-21 | 2026-07-15 |
| CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors CAR-T Therapy - CAR-T Cell Therapy, Lymphomas | Phase 1 | Not yet recruiting | Mingzhi Zhang | 30 | 2024-12-01 | 2024-10-17 |
| Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies Patients who are candidates for CAR-T cell therapy for hematologic malignancy - CAR-T Cell Therapy, Extracellular Vesicles | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 100 | 2024-08-31 | 2024-12-27 | |
| Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS anti-BCMA/CD70 CAR-T cells - Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 18 | 2024-08-13 | 2025-08-29 |
| Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV anti-CD19-CAR-T cells - ANCA Associated Vasculitis, CAR-T Cell Therapy | Withdrawn | The Children's Hospital of Zhejiang University School of Medicine | 2024-08-01 | 2026-06-16 | ||
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers Cell therapy for solid tumors - Pancreas Cancer, Lung Cancer | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2024-05-10 | 2024-06-26 |
| Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus anti-CD19-CAR-T cells - Systemic Lupus Erythematosus, CAR-T Cell Therapy | Phase 1 | Active not recruiting | The Children's Hospital of Zhejiang University School of Medicine | 22 | 2024-02-10 | 2026-02-04 |
| Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients GC012F injection - CAR-T Cell Therapy | Early Phase 1 | Recruiting | RenJi Hospital | 18 | 2023-05-11 | 2026-06-01 |
| Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers CAR-T cells - Pancreas Cancer, CAR-T Cell Therapy | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2023-03-10 | 2024-06-25 |
Showing 20 of 21. Sign in to see all of them.
Burkitt Lymphoma (2) · Cytokine Release Syndrome (2) · Nephrotic Syndrome (2) · Pancreatic Neoplasms (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Lupus Erythematosus, Systemic (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Mesothelioma (1) · Multiple Myeloma (1) · Recurrence (1)
Neoplasms (9) · Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Neoplasms by Histologic Type (6) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Site (4) · Hematologic Diseases (3) · Infections (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Autoimmune Diseases (2)
Immunotherapy, Adoptive (3) · Cyclophosphamide (2) · fludarabine (2) · Cell- and Tissue-Based Therapy (1) · Interleukin 1 Receptor Antagonist Protein (1) · Levetiracetam (1) · axicabtagene ciloleucel (1)
The Children's Hospital of Zhejiang University School of Medicine (4) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Ruijin Hospital (2) · Second Affiliated Hospital of Guangzhou Medical University (2) · Duke University (1) · First Affiliated Hospital of Zhejiang University (1) · Kevin McNerney (1) · Massachusetts General Hospital (1) · Medical University of South Carolina (1) · Mingzhi Zhang (1) · RenJi Hospital (1) · TCRCure Biopharma Ltd. (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The Cooper Health System (1) · University of Kansas Medical Center (1)
China (11) · United States (6) · Italy (2)
Jianhua Mao, PhD (2) · Zhenfeng Zhang, MD, PhD (2) · Anthony Sung, MD (1) · Baratam Praneeth, MD (1) · Jianhua Mao, MD (1) · Mo Wang, PhD (1) · Patrick C Johnson, MD (1) · Zeno Adrien Igor Pasquini (1)
PMID 28925994, PMID 30592986, PMID 30842314, PMID 31974366, PMID 32472023, PMID 34347960, PMID 36109639
K12TR005104 (1), R01NR021468 (1)